

# Pathophysiological mechanisms and Classification of Atrial Fibrillation

<sup>1</sup>Abdullah Saad ALAsmari, <sup>2</sup>ALASMARI, MESHAL ALI S, <sup>3</sup>ASIRI SAAD ALI M, <sup>4</sup>ALSHAHRANI MOHAMMED SALEH, <sup>5</sup>Ibrahim Abdulaziz Turki

---

**Abstract:** Atrial fibrillation (AF) is the most common continual arrhythmia in human beings, triggering an increasing variety of deaths and problems. Electrocardiogram (ECG)-based studies recommend that ~ 1% of the overall population is impacted. This systematic review aimed to describes the published evidence for the pathomechanisms, classification and management of atrial fibrillation (AF) and its consequences. A comprehensive structured literature search was performed using MEDLINE for studies published through October, 2016, that reported on Atrial Fibrillation pathomechanisms , concequences, classification and treatment . The search terms included each of the following terms individually and in combination: atrial fibrillation, ,classification, treatment . AF is a progressively common and typical arrhythmia that is connected with considerable morbidity and death. Since of the restricted effectiveness of catheter based treatments, specifically for patients with relentless AF, and the considerable morbidity and death connected with surgery for the arrhythmia, medicinal treatment stays the pillar of treatment for most of patients. The optimal treatment technique for patients with consistent AF stays questionable, with some clinicians favouring rhythm control and others rate control.

**Keywords:** Atrial Fibrillation, Electrocardiogram, Pathophysiological mechanisms.

---

## 1. INTRODUCTION

Atrial fibrillation (AF) is the most common continual arrhythmia in human beings, triggering an increasing variety of deaths and problems <sup>(1,2)</sup>. Electrocardiogram (ECG)-based studies recommend that ~ 1% of the overall population is impacted <sup>(3)</sup>. The variety of patients with AF is most likely to triple or double within the next 2 to 3 years <sup>(4)</sup>. The frequency of AF is plainly age reliant. The growing frequency of AF can be described in part by the increasing typical age in the human population <sup>(5)</sup>. There is likewise proof of a subtle cardiomyopathy related to atrial fibrillation <sup>(6)</sup> and a variety of case reports detailing reversible persistent cardiac arrest connected to quick unrestrained atrial fibrillation <sup>(7,8)</sup> Advances in the treatment of cardiac arrest have actually enhanced death <sup>(9)</sup> and have actually possibly caused a decrease in the occurrence of associated atrial fibrillation <sup>(10,11)</sup>, while reliable management of atrial fibrillation will enhance signs and might slow down the development of persistent cardiac arrest. In general, 20-25% of all strokes are triggered by AF <sup>(12)</sup>, and AF-related strokes are more extreme than strokes of other origin. The value of cardio-embolic stroke in AF patients is highlighted by the truth that appropriate anticoagulation in patients with AF can lower and avoid strokes death in patients at increased danger of stroke <sup>(13,14)</sup>. Left ventricular function, the best-validated scientific criterion for heart diagnosis, can be significantly impaired in AF patients and in some trials enhanced when sinus rhythm is preserved for a longer amount of time <sup>(15,16)</sup>. It is worth keeping in mind that AF-CHF, a current big trial of sinus rhythm upkeep in patients with currently significantly depressed left ventricular (LV) function, and AFFIRM, the very first big "rate versus rhythm" trial, did not discover an impact of sinus rhythm on LV function <sup>(17)</sup>. Apart from antithrombotic treatment, we have actually up until now cannot establish restorative interventions that enhance diagnosis in AF patients <sup>(17)</sup>, highlighting the requirement for much better, potentially earlier and more detailed, management of AF, as highlighted by a current agreement declaration <sup>(18)</sup>.

This systematic review aimed to describes the published evidence for the pathomechanisms, classification and management of atrial fibrillation (AF) and its consequences.

## 2. METHODOLOGY

*A systematic review study was conducted according to the guideline of reviews Search Strategy:*


A comprehensive structured literature search was performed using MEDLINE for studies published through October, 2016, that reported on Atrial Fibrillation pathomechanisms, consequences, classification and treatment. The search terms included each of the following terms individually and in combination: atrial fibrillation, , classification, treatment. We focused on primary published research articles and systematic reviews, as well as on clinical trials complemented by large observational cohorts.

### 3. RESULTS AND DISCUSSION

#### *Classification of AF:*

AF may be classified based on aetiology, depending upon whether it takes place without recognizable aetiology in patients with a structurally typical heart (only AF), or whether it makes complex hypertensive, valvar, or other structural cardiovascular disease.

We have actually consisted of 10 research studies<sup>(1,19-27)</sup> that were talking about a range of various category plans for AF, with a basis on etiology, electrophysiological attributes, temporal pattern, signs, and lifestyle have actually been proposed. The plan presently advised by the European and American cardiology societies stresses temporal rhythm-based patterns of AF (**Figure 1**)<sup>(19)</sup>. AF is categorized as 'first-detected' in patients who have no history of this arrhythmia. AF that repeats after the first-detected episode is thought about 'paroxysmal' if it self-terminates within 1 week, 'consistent' if it continues beyond this duration and is not self-terminating, or 'long-term' if efforts to end the rhythm stop working or are not tried<sup>(19)</sup> at the private level, patients are usually thought about to have the class of AF that corresponds to the rhythm that has occurred most often for the patient up to the time of assessment.



**Figure1: temporal classification of atrial fibrillation (AF).** An incident episode of AF presenting to medical attention may be the first ever detected episode of the arrhythmia, or represent recurrence of previously recognised arrhythmia (left). The episode may prove to be self terminating (paroxysmal), persistent (continuing until medical intervention such as DC cardioversion), or permanent (continuing for longer than one year or despite medical intervention such as DC cardioversion) (right).<sup>(19)</sup>

#### *pathophysiological Mechanism of AF:*

The recognition that pathophysiological procedures culminating in AF might vary in between people,<sup>(28,29)</sup> coupled with understanding that particular hereditary anomalies are related to unique electrophysiological AF systems that result in AF,<sup>(30,31)</sup> raise the possibility that people might have an intrinsic tendency to establish a specific AF pattern. Private

investigators have actually looked for to identify whether functions determined by medical history,<sup>(32)</sup> physical evaluation,<sup>(33)</sup> or molecular,<sup>(34)</sup> distributing biochemical,<sup>(35,36,37)</sup> and/or electrophysiological metrics<sup>(37,38,39)</sup> identify in between pattern-based classes or system of AF, outcomes have actually been blended. The majority of research studies are cross-sectional and single-center, and have actually not been reproduced. Observed associations in between the studied variables and AF patterns might simply serve as markers of the development of AF, and might not symbolize unique AF subtypes. A lot of research study samples are made up of patients of European origins, which restricts the capability to generalize findings to people of other races or ethnic backgrounds. Little understanding exists to relate patterns and either AF etiology or system although, as kept in mind above, patterns might identify degrees of substrate problems or improvement. Comprehending the systems of AF might assist in efforts to identify whether a tendency to establish particular rhythm-based patterns of AF exists, and if so, might offer more validation for rhythm-based classification of AF<sup>(37,38,39)</sup>.

#### **Pharmacological management of AF:**

In the DAAF (Digitalis in Acute Atrial Fibrillation) One included trial<sup>(40)</sup> of the 28 patients who had cardiac arrest no distinction was seen in cardioversion rates at 16 h in between placebo and intravenous digoxin.

Galve et al.<sup>(24)</sup> compared intravenous amiodarone and placebo in a randomized regulated trial. Eleven of the 100 patients struggled with moderate persistent cardiac arrest; extreme persistent cardiac arrest was left out. Digoxin was administered at a dosage of 1 - 5 mg over 24 h to both groups of patients. If both were in the amiodarone group this represents a low rate of cardioversion, just 2 out of the 11 heart failure patients transformed to sinus rhythm and even. The existence of cardiac arrest anticipated a lower probability of cardioversion. Hou et al.<sup>(42)</sup> compared intravenous amiodarone to intravenous digoxin in an open-label randomized research study of unrestrained atrial fibrillation. Forty-six percent of patients in the digoxin group and 54% of patients in the amiodarone remained in NYHA (New York Heart Association) class IV. Eleven patients had ischaemic heart problem of which 7 had actually been confessed with a myocardial infarction. Seventeen patients (34%) were getting inotropic treatment however just 10 (20%) were getting ACE inhibitors. Groups were well matched, apart from the mean period of atrial fibrillation, which were 4 and 14 h in the digoxin and amiodarone groups respectively (P1 h with digoxin. Goldenberg et al.<sup>(43)</sup> compared intravenous diltiazem with placebo in a double-blind research study followed by administration of open-label diltiazem to non-responders. Serious persistent cardiac arrest, specified as an ejection fraction.

## **4. CONCLUSION**

AF is a progressively common and typical arrhythmia that is connected with considerable morbidity and death. Since of the restricted effectiveness of catheter based treatments, specifically for patients with relentless AF, and the considerable morbidity and death connected with surgery for the arrhythmia, medicinal treatment stays the pillar of treatment for most of patients. The optimal treatment technique for patients with consistent AF stays questionable, with some clinicians favouring rhythm control and others rate control. The pathogenesis of AF is now believed to include an interaction in between starting triggers, frequently through quickly shooting ectopic foci situated inside several lung veins, and an unusual atrial tissue substrate efficient in preserving the arrhythmia. Structural heart disease underlies numerous cases of AF, the pathogenesis of AF in obviously regular hearts is less well comprehended. There is significant overlap, lung vein sets off might play a dominant function in more youthful patients with fairly typical hearts and brief paroxysms of AF, whereas an unusual atrial tissue substrate might play a more crucial function in patients with structural heart disease and long-term or relentless AF. The primary focus of current advancements in medicinal treatment for AF has actually been the advancement of unique class III antiarrhythmic representatives, each with particular results on potassium channels. In basic, these representatives have actually shown reasonably effective however bring a substantial danger of proarrhythmia. While research study in this field continues, other drugs such as particular serotonin receptor villains continue to be established. Additional advancements in catheter ablation innovations might significantly help with safe seclusion of several lung veins for patients with mainly paroxysmal AF, whereas improvements in linear catheter ablation technologies

## **REFERENCES**

- [1] Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Page | 401

- Zamorano JL, Smith SC Jr., Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Eur Heart J* 27: 1979–2030, 2006.
- [2] Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns H, Diener HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S, Page RL, Ravens U, Schotten U, Steinbeck G, Vardas P, Waldo A, Wegscheider K, Willems S, Breithardt G. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference “research perspectives in AF.” *Eur Heart J* 30: 2969–2977, 2009.
- [3] Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. *Am J Cardiol* 82: 2N–9N, 1998.
- [4] Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, Raftery J, Davies M, Lip G. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. *The SAFE study Health Technol Assess* 9: iii-iv, ix-x, 1–74, 2005.
- [5] Camm AJ, Kirchhof P, Lip G, Savelieva I, Ernst S. Atrial fibrillation. In: *The ESC Textbook of Cardiology*, edited by Camm AJ, Serruys PW, Luscher T2009.
- [6] Van Den Berg MP, Tuinenberg AE, Crijns HJGM, Van Gelder IC, Gosselink ATM, Lie KI. Heart failure and atrial fibrillation: current concepts and controversies. *Heart* 1997; 77: 309–13.
- [7] Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. *Am J Cardiol* 1992; 69: 1570–3.
- [8] Peters KG, Kienzle MG. Severe cardiomyopathy due to chronically rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm. *Am J Med* 1988; 85: 242–4.
- [9] Haiat R, Halphen C, Stoltz JP, Leroy G, Sousanna C. Atrial fibrillation: a cause of reversible cardiomyopathy. *Ann Cardiol Angeiol* 1987; 36: 417–9.
- [10] Brill IC. Congestive cardiac failure arising from uncontrolled auricular fibrillation in the otherwise normal heart: follow-up notes on a previously reported case. *Am J Med* 1947; 2: 544.
- [11] Phillips E, Levine SA. Auricular fibrillation without other evidence of heart disease: a cause of reversible heart failure. *Am J Med* 1949; 7: 478.
- [12] Swedberg K, Idanpaan Heikkila U, Remes J, and CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Coperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med* 1987; 316: 1429–35.
- [13] Pedersen OD, Bagger H, Torp-Pederson C. Trandolapril reduces incidence of atrial fibrillation following acute myocardial infarction. *Circulation* 1999; 100: 376–80. [21] Van Den Berg MG, Crijns HJGM, Veldhuisen DJV et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. *J Cardiac Failure* 1995; 1: 355–63.
- [14] Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Seward JB, Bailey KR, Iwasaka T, Tsang TS. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. *Stroke* 36: 2362–2366, 2005.
- [15] Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 361: 1139–1151, 2009.
- [16] Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med* 131: 492–501, 1999.

- [17] Hsu LF, Jais P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquie JL, Scavee C, Bordachar P, Clementy J, Haissaguerre M. Catheter ablation for atrial fibrillation in congestive heart failure. *N Engl J Med* 351: 2373–2383, 2004.
- [18] Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL. Rhythm control versus rate control for atrial fibrillation and heart failure. *N Engl J Med* 358: 2667–2677, 2008.
- [19] Wells JL, Jr, et al. Characterization of atrial fibrillation in man: studies following open heart surgery. *Pacing Clin Electrophysiol.* 1978;1:426–438.
- [20] Konings KT, et al. High-density mapping of electrically induced atrial fibrillation in humans. *Circulation.* 1994;89:1665–1680.
- [21] Sopher SM, Camm AJ. Therapy for atrial fibrillation: control of the ventricular response and prevention of recurrence. *Coron Artery Dis.* 1995;6:106–114.
- [22] Levy S, Novella P, Ricard P, Paganelli F. Paroxysmal atrial fibrillation: a need for classification. *J Cardiovasc Electrophysiol.* 1995;6:69–74.
- [23] Gallagher MM, Camm AJ. Classification of atrial fibrillation. *Pacing Clin Electrophysiol.* 1997;20:1603–1605.
- [24] Levy S, et al. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. *Eur Heart J.* 1998;19:1294–1320.
- [25] Levy S. Classification system of atrial fibrillation. *Curr Opin Cardiol.* 2000;15:54–57.
- [26] Reynolds MR, Ellis E, Zimetbaum P. Quality of life in atrial fibrillation: measurement tools and impact of interventions. *J Cardiovasc Electrophysiol.* 2008;19:762–768.
- [27] Lane DA, Lip GY. Quality of life in older people with atrial fibrillation. *J Interv Card Electrophysiol.* 2009;25:37–42.
- [28] Allessie MA, et al. Pathophysiology and prevention of atrial fibrillation. *Circulation.* 2001;103:769–777.
- [29] Nattel S. New ideas about atrial fibrillation 50 years on. *Nature.* 2002;415:219–226.
- [30] Roberts JD, Gollob MH. Impact of Genetic Discoveries on the Classification of Lone Atrial Fibrillation. *J Am Coll Cardiol.* 2010;55:705–712.
- [31] Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrial fibrillation caused by mutation in *KCNH2*. *J Cardiovasc Electrophysiol.* 2005;16:394–396.
- [32] Coumel P. Paroxysmal atrial fibrillation: a disorder of autonomic tone? *Eur Heart J.* 1994;(15 Suppl A):9–16.
- [33] Nabauer M, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. *Europace.* 2009;11:423–434. Gramley F, et al. Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. *J Cardiovasc Electrophysiol.* 2007;18:1076–1082.
- [34] Chung MK, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. *Circulation.* 2001;104:2886–2891.
- [35] Li-Saw-Hee FL, Blann AD, Gurney D, Lip GY. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. *Eur Heart J.* 2001;22:1741–1747.
- [36] Kamath S, Chin BS, Blann AD, Lip GY. A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation. *Blood Coagul Fibrinolysis.* 2002;13:627–636.
- [37] Tziakas DN, et al. Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation. *Europace.* 2007;9:589–596.

- [38] Freestone B, Chong AY, Nuttall S, Blann AD, Lip GY. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. *Chest*. 2007;132:1253–1258.
- [39] Gaita F, et al. Different patterns of atrial activation in idiopathic atrial fibrillation: simultaneous multisite atrial mapping in patients with paroxysmal and chronic atrial fibrillation. *J Am Coll Cardiol*. 2001;37:534–541.
- [40] The digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Results of a randomized, placebo-controlled multicentre trial in 239 patients. *Eur Heart J* 1997; 18: 649–54.
- [41] Galve E, Rius T, Ballester R et al. Intravenous Amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study. *J Am Coll Cardiol* 1996; 27: 1079–82.
- [42] Hou ZY, Chang MS, Chen CY et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. *Eur Heart J* 1995; 16: 521–8.
- [43] Goldenberg IF, Lewis WR, Dias VC, Heywood JT, Pederson WR. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive cardiac failure. *Am J Cardiol* 1994; 74: 884–9.